Ann Dunne - Search Results

Year	Number of Results
2012	1
2013	2
2014	2
2015	1
2017	1
2020	1
2024	0

1

ARA 290 for treatment of small fiber neuropathy in sarcoidosis.

van Velzen M, Heij L, Niesters M, Cerami A, Dunne A, Dahan A, Brines M. van Velzen M, et al. Among authors: dunne a. Expert Opin Investig Drugs. 2014 Apr;23(4):541-50. doi: 10.1517/13543784.2014.892072. Epub 2014 Feb 21. Expert Opin Investig Drugs. 2014. PMID: 24555851 Review.

2

A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.

Lois N, Gardner E, McFarland M, Armstrong D, McNally C, Lavery NJ, Campbell C, Kirk RI, Bajorunas D, Dunne A, Cerami A, Brines M. Lois N, et al. Among authors: dunne a. J Clin Med. 2020 Jul 14;9(7):2225. doi: 10.3390/jcm9072225. J Clin Med. 2020. PMID: 32674280 Free PMC article.

3

Ketamine does not produce relief of neuropathic pain in mice lacking the β-common receptor (CD131).

Swartjes M, Niesters M, Heij L, Dunne A, Aarts L, Hand CC, Kim HS, Brines M, Cerami A, Dahan A. Swartjes M, et al. Among authors: dunne a. PLoS One. 2013 Aug 1;8(8):e71326. doi: 10.1371/journal.pone.0071326. Print 2013. PLoS One. 2013. PMID: 23936499 Free PMC article.

4

ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.

Dahan A, Dunne A, Swartjes M, Proto PL, Heij L, Vogels O, van Velzen M, Sarton E, Niesters M, Tannemaat MR, Cerami A, Brines M. Dahan A, et al. Among authors: dunne a. Mol Med. 2013 Nov 8;19(1):334-45. doi: 10.2119/molmed.2013.00122. Mol Med. 2013. PMID: 24136731 Free PMC article. Clinical Trial.

5

Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.

Culver DA, Dahan A, Bajorunas D, Jeziorska M, van Velzen M, Aarts LPHJ, Tavee J, Tannemaat MR, Dunne AN, Kirk RI, Petropoulos IN, Cerami A, Malik RA, Brines M. Culver DA, et al. Among authors: dunne an. Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO52-BIO60. doi: 10.1167/iovs.16-21291. Invest Ophthalmol Vis Sci. 2017. PMID: 28475703 Clinical Trial.

6

ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.

Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Kirk RI, Petropoulos IN, Javed S, Malik RA, Cerami A, Dahan A. Brines M, et al. Among authors: dunne an. Mol Med. 2015 Mar 13;20(1):658-66. doi: 10.2119/molmed.2014.00215. Mol Med. 2015. PMID: 25387363 Free PMC article. Clinical Trial.

7

ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response.

Swartjes M, van Velzen M, Niesters M, Aarts L, Brines M, Dunne A, Cerami A, Dahan A. Swartjes M, et al. Among authors: dunne a. Mol Pain. 2014 Feb 16;10:13. doi: 10.1186/1744-8069-10-13. Mol Pain. 2014. PMID: 24529189 Free PMC article.

8

Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.

Heij L, Niesters M, Swartjes M, Hoitsma E, Drent M, Dunne A, Grutters JC, Vogels O, Brines M, Cerami A, Dahan A. Heij L, et al. Among authors: dunne a. Mol Med. 2012 Nov 15;18(1):1430-6. doi: 10.2119/molmed.2012.00332. Mol Med. 2012. PMID: 23168581 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

8 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year